The FDA has told Evolus that an Instagram reel promoting its wrinkle injection Jeuveau misbranded the drug by likening it to everyday beauty products and minimizing its risks. The agency's Office of Prescription Drug Promotion sent the untitled letter Sept. 28 and asked the company to respond within 15 working days.
The issue goes beyond one social media post. The reel presented a prescription injection as part of a beauty routine, yet Jeuveau carries a boxed warning, the FDA's most serious safety label. Consumers deciding where and how to get treatment need to understand that difference.
